SRx Health stock soars after deal to acquire Eric Jackson’s digital asset treasury platform

Investing.com -- Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 3.5% after the company announced positive interim data from its Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide for treating metastatic castration-resistant prostate cancer (mCRPC).

The clinical-stage biotechnology company reported a 100% PSA response rate and 100% disease control rate in patients with androgen receptor (AR) mutations. Among the four patients with AR mutations, two showed RECIST partial responses while two maintained stable disease. The overall disease control rate across all 14 evaluable patients was 64%.

Monte Rosa’s MRT-2359, an orally bioavailable molecular glue degrader targeting GSPT1, demonstrated a favorable safety profile when combined with enzalutamide. Patients primarily experienced mild to moderate gastrointestinal adverse events (Grade 1-2).

"We continue to be highly encouraged by the clinical activity observed with MRT-2359 in combination with enzalutamide in heavily pretreated mCRPC patients, a population with limited therapeutic options," said Markus Warmuth, CEO of Monte Rosa Therapeutics.

The study population included 20 heavily pretreated individuals with advanced CRPC, with 75% previously treated with a second-generation AR inhibitor, 80% with taxane chemotherapy, and 55% with Pluvicto.

Based on these results, Monte Rosa plans to initiate a new signal-confirming Phase 2 study in 2026, evaluating MRT-2359 in combination with a second-generation AR inhibitor in mCRPC patients with AR mutations. The company expects to present updated data at the ASCO Genitourinary Cancers Symposium in February 2026.

The company also announced plans to present interim Phase 1 data on MRT-8102, its NEK7-directed molecular glue degrader for inflammatory diseases, in early 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com – Indonesia stocks were higher after the close on Tuesday, as gains in the Agriculture, Basic Industry and Property sectors led shares higher.

At the close in Jakarta, the IDX Composite Index gained 0.02%.

The best performers of the session on the IDX Composite Index were Pelayaran Nasional Bina Buana Raya (JK:BBRM), which rose 32.20% or 38.00 points to trade at 156.00 at the close. Meanwhile, Green Power Group Tbk PT (JK:LABA) added 30.82% or 45.00 points to end at 191.00 and Makmur Berkah Amanda Pt (JK:AMAN) was up 28.80% or 55.00 points to 246.00 in late trade.

The worst performers of the session were Bali Towerindo Sentra Tbk (JK:BALI), which fell 14.98% or 325.00 points to trade at 1,845.00 at the close. Alkindo Naratama Tbk (JK:ALDO) declined 14.86% or 110.00 points to end at 630.00 and Eratex Djaja Tbk (JK:ERTX) was down 14.84% or 38.00 points to 218.00.

Rising stocks outnumbered declining ones on the Jakarta Stock Exchange by 345 to 335 and 158 ended unchanged.

Shares in Pelayaran Nasional Bina Buana Raya (JK:BBRM) rose to 5-year highs; up 32.20% or 38.00 to 156.00. Shares in Makmur Berkah Amanda Pt (JK:AMAN) rose to 52-week highs; up 28.80% or 55.00 to 246.00.

Crude oil for February delivery was down 1.25% or 0.71 to $55.96 a barrel. Elsewhere in commodities trading, Brent oil for delivery in February fell 1.22% or 0.74 to hit $59.82 a barrel, while the February Gold Futures contract fell 0.63% or 27.45 to trade at $4,307.75 a troy ounce.

USD/IDR was up 0.22% to 16,673.50, while AUD/IDR rose 0.18% to 11,082.16.

The US Dollar Index Futures was down 0.07% at 97.89.

Investing.com -- Serica Energy has agreed to purchase a portfolio of Southern North Sea assets from Spirit Energy Limited for £57 million ($74 million), with completion expected in the second half of 2026.

The acquisition includes a 15% non-operated stake in the Cygnus gas field, a 25% interest in Clipper South, operated positions in the Greater Markham Area, and interests in Eris, Ceres, and Galleon gas fields. Spirit Energy will retain over 75% of the total decommissioning liabilities.

The deal adds 18.7 million barrels of oil equivalent (mmboe) in 2P reserves, increasing Serica’s reserves by 16% at a cost of approximately $3.9 per barrel. It also contributes around 13,500 barrels of oil equivalent per day (boepd) in production, of which 96% is gas.

"This transaction is a further step towards delivering on our strategy and diversifying our asset base through the addition of high-quality assets," said Chris Cox, Serica’s CEO. "These are also assets I personally know well, and the Cygnus field in particular is an attractive addition to our portfolio given its high uptime, low emissions, and low operating costs."

The Cygnus field, one of the largest producing gas fields in the UK Continental Shelf, has a carbon intensity of 7 kgCO2/boe, well below the North Sea average. It features operating costs of approximately $11/boe and achieved 97% operating efficiency in the first half of 2025.

The transaction has an effective economic date of January 1, 2025, with the upfront consideration expected to be significantly offset by interim post-tax cash flows generated between the effective date and completion.

Serica confirmed that the acquisition does not impact its planned move from AIM to the Main Market of the London Stock Exchange, which is still expected at the earliest viable opportunity in 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.